Abstract:Background: Metastasis is the leading cause of death in colorectal cancer (CRC) patients. It is regulated mainly by tumor cell angiogenesis, and angiogenesis is caused by the binding of vascular endothelial growth factor (VEGF) to vascular endothelial growth factor receptor 2 (VEGFR2). Tumor necrosis factor-alpha-induced protein 8 (TNFAIP8, hereto after TIPE) plays an important role in tumorigenesis, development, and prognosis. However, the relationship between TIPE and VEGFR2 in CRC angiogenesis and the mechanism of action remain unknown. Method: In this study, we used quantitative real-time PCR, Western blotting and immunohistochemistry to detect TIPE and VEGFR2 expression in 55 specimens from CRC patients. We also used HCT116 CRC cells and human umbilical vein endothelial cells (HUVECs) for in vitro experiments by stably transducing shTIPE and shRNA control lentivirus into HCT116 cells, detecting VEGFR2 expression after TIPE knockdown and repurposing the culture supernatant as conditioned medium to stimulate angiogenesis of HUVECs. In vivo experiments with chicken chorioallantoic membranes (CAMs) and a nude mouse matrix subcutaneous tumor model were performed to validate the effects of TIPE on angiogenesis. Additionally, we analyzed the expression and phosphorylation levels of PDK1 and blocked PDK1 expression using inhibitors to determine whether TIPE-induced changes in VEGFR2-mediated angiogenesis acted via the PI3K-Akt pathway. Results: We found that TIPE and VEGFR2 are highly expressed in CRC and act as oncogenes. TIPE knockdown also downregulated VEGFR2 expression, which resulted in simultaneous inhibition of cell proliferation, cell migration and angiogenesis. Then, in vivo experiments further demonstrated that TIPE promotes angiogenesis in CRC. Finally, we found that TIPE promotes VEGFR2-mediated angiogenesis by upregulating PDK1 expression and phosphorylation and that blocking PDK1 expression can inhibit this process. Conclusion: TIPE promotes angiogenesis in CRC by regulating the expression of VEGFR2, which may be a target for antiangiogenic cancer therapy.

Gene Delivery of TIPE2 Inhibits Breast Cancer Development and Metastasis Via CD8+ T and NK Cell-Mediated Antitumor Responses.

Tipe2 Suppresses the Tumorigenesis, Growth and Metastasis of Breast Cancer Via Inhibition of the Akt and P38 Signaling Pathways

Tumor Necrosis Factor (Tnf)-Α-induced Protein 8-Like-2 (TIPE2) Inhibits Proliferation and Tumorigenesis in Breast Cancer Cells.

TIPE2 Suppresses Malignancy of Pancreatic Cancer Through Inhibiting TGFβ1 Mediated Signaling Pathway

TIPE2 suppresses angiogenesis and non-small cell lung cancer (NSCLC) invasiveness via inhibiting Rac1 activation and VEGF expression.

Adenovirus-directed Expression of TIPE2 Suppresses Gastric Cancer Growth Via Induction of Apoptosis and Inhibition of AKT and ERK1/2 Signaling

TIPE3 Protein Promotes Breast Cancer Metastasis Through Activating AKT and NF-κB Signaling Pathways

TIPE2 inhibits melanoma progression through MEK/ERK signaling

Tipe2 Functions As A Metastasis Suppressor Via Negatively Regulating Beta-Catenin Through Activating Gsk3 Beta In Gastric Cancer

Adenovirus-mediated TIPE2 Overexpression Inhibits Gastric Cancer Metastasis Via Reversal of Epithelial–mesenchymal Transition

TIPE2 Inhibits GC Via Regulation of Cell Proliferation, Apoptosis and Inflammation

TIPE Regulates VEGFR2 Expression and Promotes Angiogenesis in Colorectal Cancer.

TIPE2 Suppresses Progression and Tumorigenesis of Esophageal Carcinoma Via Inhibition of the Wnt/β-catenin Pathway

Tipe2 Inhibits Lung Cancer Growth Attributing To Promotion Of Apoptosis By Regulating Some Apoptotic Molecules Expression

TIPE2 Sensitizes Breast Cancer Cells to Paclitaxel by Suppressing Drug-Induced Autophagy and Cancer Stem Cell Properties.

Human Tumor Necrosis Factor (Tnf)-Alpha-induced Protein 8-Like 2 Suppresses Hepatocellular Carcinoma Metastasis Through Inhibiting Rac1.

TIPE1 Suppresses Growth and Metastasis of Ovarian Cancer

A Novel Prognostic Factor TIPE2 Inhibits Cell Proliferation and Promotes Apoptosis in Pancreatic Ductal Adenocarcinoma (PDAC)

TIPE2 Acts As a Biomarker for GIST Risk Category and Suppresses the Viability and Invasiveness of GIST Cells.

TIPE2 inhibits the migration and invasion of epithelial ovarian cancer cells by targeting Smad2 to reverse TGF-β1-induced EMT

TIPE2: A Candidate for Targeting Antitumor Immunotherapy.